- Home
- QTRX vs TSHA Comparison
QTRX vs TSHA Comparison
Compare QTRX & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QTRX
- TSHA
- Stock Information
- Founded
- QTRX 2007
- TSHA 2019
- Country
- QTRX United States
- TSHA United States
- Employees
- QTRX N/A
- TSHA N/A
- Industry
- QTRX Biotechnology: Laboratory Analytical Instruments
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- QTRX Industrials
- TSHA Health Care
- Exchange
- QTRX Nasdaq
- TSHA Nasdaq
- Market Cap
- QTRX 439.1M
- TSHA 403.7M
- IPO Year
- QTRX 2017
- TSHA 2020
- Fundamental
- Price
- QTRX $11.72
- TSHA $2.18
- Analyst Decision
- QTRX Strong Buy
- TSHA Strong Buy
- Analyst Count
- QTRX 4
- TSHA 8
- Target Price
- QTRX $23.25
- TSHA $6.63
- AVG Volume (30 Days)
- QTRX 465.3K
- TSHA 6.7M
- Earning Date
- QTRX 11-12-2024
- TSHA 11-13-2024
- Dividend Yield
- QTRX N/A
- TSHA N/A
- EPS Growth
- QTRX N/A
- TSHA N/A
- EPS
- QTRX N/A
- TSHA N/A
- Revenue
- QTRX $129,330,000.00
- TSHA $9,915,000.00
- Revenue This Year
- QTRX $13.56
- TSHA N/A
- Revenue Next Year
- QTRX $16.49
- TSHA N/A
- P/E Ratio
- QTRX N/A
- TSHA N/A
- Revenue Growth
- QTRX 15.52
- TSHA N/A
- 52 Week Low
- QTRX $10.50
- TSHA $1.19
- 52 Week High
- QTRX $29.70
- TSHA $4.32
- Technical
- Relative Strength Index (RSI)
- QTRX 41.00
- TSHA 56.47
- Support Level
- QTRX $14.72
- TSHA $1.96
- Resistance Level
- QTRX $15.46
- TSHA $2.34
- Average True Range (ATR)
- QTRX 0.92
- TSHA 0.26
- MACD
- QTRX -0.37
- TSHA 0.06
- Stochastic Oscillator
- QTRX 18.56
- TSHA 68.75
About QTRX Quanterix Corporation
Quanterix Corp is a life sciences company. It focuses on developing an ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics. The Simoa bead-based and planar array platforms designed by the company enable customers to reliably detect protein biomarkers in low concentrations in blood, serum, and other fluids that are undetectable using conventional, analog immunoassay technologies. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, Instruments, HD-X Automated Immunoassay Analyzer, SR-X Biomarker Detection System, SP-X Imaging and Analysis System, Simoa Accelerator Laboratory, Homebrew - Custom Assay Development, and Uman NF-Light.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.